MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 11..20 of 35 - per page Previous page Next page
Order by
Multiple immortalized, malignant, human, adult prostate epithelial cell lines useful as models in epithelial cell oncogenesis studies and in the diagnosis and treatment of prostate cancer More
Grape skin extract, or purified fractions thereof, inhibited metastatic growth in human prostate transformed cell lines More
Angiogenesis, cancer, diabetic retinopathy, tilted peptide More
Identification and characterization of novel PAGE4 cytotoxic T-cell lymphocyte (CTL) epitopes and enhanced agonist epitopes. More
New immunotoxins comprising a mutant diphtheria toxin linked to an anti-prostate specific membrane antigen (PSMA) fold-back diabody More
This technology will allow generating entire novel methods for screening, treatment and prevention of androgen resistant prostate cancer, a devastating disease responsible for more male deaths than any other cancer, except lung cancer. More
Through in vitro and in vivo tumor suppression experiments, the inventors have demonstrated that DLC-1 acts as a new tumor suppressor gene for different types of human cancer. More
This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. More
This technology concerns separate inventions to specific compositions of hyaluronan (HA) fragments and/or agents useful for wound healing or the treatment of cancer. More
Displaying 11..20 of 35 - per page Previous page Next page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us